Choose A Condition: PLEASE SELECT MODERATELY TO SEVERELY ACTIVE RA ACTIVE PSORIATIC ARTHRITIS ACTIVE ANKYLOSING SPONDYLITIS Home Efficacy ACR Response in RA Inhibition of Radiographic Progression in RA HAQ-DI Scores in RA SF-36 Scores in RA Safety Safety Profile in RA: Placebo-Controlled Phase Safety Profile in RA: Controlled and Uncontrolled Phase Home Efficacy ACR Response in PsA Inhibition of Radiographic Progression in PsA Enthesitis/Dactylitis in PsA HAQ-DI in PsA SF-36 Scores in PsA PASI Response in PsA Safety Safety Profile in PsA: Placebo-Controlled Phase Home Efficacy ASAS Response BASDAI Scores BASFI/BASMI Scores ASQoL Scores ASAS Partial Remission Data Safety Safety Profile in AS: Placebo-Controlled Phase Home Efficacy Safety About SIMPONI ARIA® About SIMPONI ARIA® Dosing and Administration Dosing Dosing Calculator Interactive Infusion Video Administration Instructions Access and Affordability First-line Access Contract Purchase Program Resources And Support Janssen CarePath Additional Resources Important Safety Information Medical Information Center Request Information Patient Website
FOR ADULTS WITH ACTIVE PsA SIMPONI ARIA® is ready to fight the symptoms of active PsA. ABOUT SIMPONI ARIA® Learn about the only IV anti-TNF therapy DEMONSTRATED EFFICACY Explore PsA treatment results with SIMPONI ARIA® with or without MTX from a clinical trial EFFICIENT INFUSION Provide patients with a 30-minute infusion once every 8 weeks after 2 starter doses at Weeks 0 and 41,2 "Efficient" is defined as the total amount of time required to administer SIMPONI ARIA® LEARN MORE Provide patients with a 30-minute infusion once every 8 weeks after 2 starter doses at Weeks 0 and 41,2 "Efficient" is defined as the total amount of time required to administer SIMPONI ARIA® LEARN MORE
DEMONSTRATED EFFICACY Explore PsA treatment results with SIMPONI ARIA® with or without MTX from a clinical trial
REQUEST INFORMATION
